ReproCell Inc is a leading company in the field of stem cell research and drug discovery. Their business model revolves around providing innovative solutions for regenerative medicine through the development of human-derived stem cell products and services. ReproCell Inc focuses on utilizing induced pluripotent stem cells (iPSCs) to generate disease-specific models for drug screening and toxicity testing. By offering high-quality iPSC-derived products, such as neural cells, hepatocytes, and cardiomyocytes, ReproCell aims to meet the diverse needs of the pharmaceutical industry, academic research, and clinical applications. With their expertise in stem cell technology, ReproCell Inc is dedicated to advancing the development of personalized medicine and improving patient outcomes.

ReproCell Inc is primarily active in the biotechnology and pharmaceutical industries. Their expertise lies in providing advanced solutions for stem cell research and drug discovery. With a focus on regenerative medicine, ReproCell Inc utilizes cutting-edge technology and innovative approaches to develop and commercialize cell-based products and services. Their commitment to advancing biomedical research and improving healthcare makes ReproCell Inc a key player in the biotech and pharma sectors.

The primary competitors of ReproCell Inc in the market include Stemcell Technologies Inc, Thermo Fisher Scientific Inc, Cellsignia, BioTime Inc, and ATCC (American Type Culture Collection).

ReproCell Inc is a renowned company specializing in stem cell research and regenerative medicine. Established in 2003, the company has made significant contributions to advancing the field of personalized medicine. With its headquarters in Yokohama, Japan, ReproCell Inc offers an extensive range of products and services related to iPSC (induced pluripotent stem cell) technology, including drug discovery, toxicity testing, and disease modeling. The company's strong commitment to innovation and quality has led to collaborations with various esteemed pharmaceutical and biotech companies worldwide. Through continuous research and development, ReproCell Inc strives to revolutionize the healthcare industry and improve patients' lives globally.

Some significant milestones achieved by ReproCell Inc include becoming a global leader in the field of stem cell research, development, and services. The company has successfully developed innovative stem cell technologies and products that have revolutionized the medical industry. ReproCell Inc has also formed strategic partnerships with leading pharmaceutical companies, enabling them to accelerate drug discovery and development processes. Additionally, the company has expanded its presence worldwide, establishing branches and subsidiaries in various countries. Through its continuous dedication to advancing stem cell therapies and services, ReproCell Inc has gained recognition as a pioneering force in the biomedical field.

ReproCell Inc is primarily present in multiple countries and regions. It has a significant presence in Japan, where the company is headquartered. Additionally, ReproCell Inc has expanded its operations to the United States, Europe, and several Asian countries such as China, South Korea, and Singapore. This global presence enables ReproCell Inc to reach a diverse customer base and collaborate with top researchers and institutions worldwide. With its strong foothold in these countries and regions, ReproCell Inc continues to establish itself as a leading provider of innovative products and services in the field of regenerative medicine and drug discovery.

ReproCell Inc represents values and a corporate philosophy centered on advancing stem cell research and regenerative medicine. As a leading company in this field, ReproCell Inc is committed to providing innovative solutions and services that contribute to global healthcare. Their philosophy revolves around utilizing cutting-edge technologies to develop safe and effective therapies, while prioritizing ethical practices and compliance with regulations. ReproCell Inc's dedication to excellence, integrity, and collaboration enables them to drive advancements in stem cell research, drug discovery, and personalized medicine. With a focus on improving patient outcomes, ReproCell Inc continues to lead with their expertise and passion in the field of regenerative medicine.

Analysts currently set an average price target of 275,40 JPY for the ReproCell stock (median: 275,40 JPY), implying +122,1 % versus the latest price. The consensus is based on 7 analyst ratings.

ReproCell Analītiķu cenu mērķi 2026

7 analysts currently rate the ReproCell stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect ReproCell to generate revenue of 3,17 B JPY and earnings per share of 0,80 JPY.

ReproCell Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the ReproCell share trades at 0,66 EUR (122,00 JPY).

The ReproCell share (4978.T) is listed on 2 stock exchanges, including: Frankfurt (6RC.F).

ReproCell Inc is a leading provider of biological materials and services for biopharmaceutical research. The company was founded in Japan in 2003 and has since expanded its presence in the global market. ReproCell's business model is based on three core areas: cell biology, tissue biology, and pharmaceutical research. These business areas are divided into various product categories and services. In the field of cell biology, ReproCell offers a wide range of primary and immortalized cell lines for research purposes. These cell lines are of the highest quality and are used in biochemistry, molecular biology, toxicology, and medical research. ReproCell also offers services such as cell isolation and cell cultivation. In addition, the company specializes in the production of cell products such as cell culture media, cell reagents, and cell beds. In the tissue biology business area, ReproCell offers unique tissue models for research purposes. These include three-dimensional cell models (e.g. organoids) and various human tissue models (e.g. liver, heart, kidney). These tissue models are ideal for studying drug toxicity and developing new treatment options. In the pharmaceutical research field, ReproCell offers a comprehensive range of services for preclinical tests. These include drug toxicity testing, concentration determination, genotyping, and pharmacokinetic testing. The company has extensive expertise in conducting in vivo studies and can offer its customers complete study packages. ReproCell also has the ability to develop custom solutions for biopharmaceutical companies. The company can assist its customers in developing custom cell models and conducting specific tests and studies. ReproCell has extensive experience in collaborating with leading biopharmaceutical companies around the world. ReproCell's business model is based on high quality and reliability. The company has an experienced and qualified team of scientists and experts specializing in research work. ReproCell constantly invests in research and development to ensure that it always offers its customers the latest and most innovative products and services. The company has customers in academia, the biopharmaceutical industry, and clinical research. ReproCell is able to serve its customers worldwide and has branches in Japan, North America, and Europe. Overall, ReproCell has established itself as an important player in biopharmaceutical research and offers a wide range of products and services. With a strong focus on quality and reliability and a broad customer base, the company is well positioned to continue growing in the future.

gaidāmā apgrozījums ReproCell ir 3,17 B JPY. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa ReproCell ir 74,28 M JPY. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

ReproCell cenas un peļņas rādītājs (P/E) pašlaik ir 152,50. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt ReproCell akcijas vērtību.

ReproCell cenas un apgrozījuma rādītājs (P/S) pašlaik ir 3,57. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā ReproCell akcijas vērtības mērs.

ReproCell Eulerpool kvalitātes rādītājs ir 3/10.

ReproCell ISIN ir JP3974770004. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

ReproCell WKN ir A1W0R7. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

ReproCell tikeris ir 4978.T. Tikeris tiek izmantots ReproCell akciju tirdzniecībai biržā.

ReproCell pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

ReproCell tiek piešķirts nozarei "Veselība".

ReproCell dividendes tiek izmaksātas JPY.